[go: up one dir, main page]

BG105569A - Метод за лечение на захарен диабет тип 2 - Google Patents

Метод за лечение на захарен диабет тип 2

Info

Publication number
BG105569A
BG105569A BG105569A BG10556901A BG105569A BG 105569 A BG105569 A BG 105569A BG 105569 A BG105569 A BG 105569A BG 10556901 A BG10556901 A BG 10556901A BG 105569 A BG105569 A BG 105569A
Authority
BG
Bulgaria
Prior art keywords
diabetes mellitus
treatment
type
insulin sensitiser
plasma
Prior art date
Application number
BG105569A
Other languages
English (en)
Other versions
BG65577B1 (bg
Inventor
Lisa Benincosa
William Jusko
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG105569(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of BG105569A publication Critical patent/BG105569A/bg
Publication of BG65577B1 publication Critical patent/BG65577B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

По метода се лекува захарен диабет тип 2 и състояния, свързани с него. Той се състои от прилагане на ефективно нетоксично количество от инсулиново антитяло, така че да се осигури плазмена концентрация на антитялото, най-малко при начално ниво (начална плазмена концентрация) от интервала на ефективните плазмени нива. Изобретението се отнася също до състави и до методология за определяне на концентрации на активно средство в плазма съгласно методите.
BG105569A 1998-11-12 2001-06-07 Фармацевтичен състав с продължително освобождаване и неговото използване BG65577B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9824893.3A GB9824893D0 (en) 1998-11-12 1998-11-12 Novel method of treatment

Publications (2)

Publication Number Publication Date
BG105569A true BG105569A (bg) 2002-01-31
BG65577B1 BG65577B1 (bg) 2009-01-30

Family

ID=10842389

Family Applications (2)

Application Number Title Priority Date Filing Date
BG110061A BG110061A (bg) 1998-11-12 2001-06-07 Фармацевтичен състав с импулсно освобождаване и неговото използване
BG105569A BG65577B1 (bg) 1998-11-12 2001-06-07 Фармацевтичен състав с продължително освобождаване и неговото използване

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BG110061A BG110061A (bg) 1998-11-12 2001-06-07 Фармацевтичен състав с импулсно освобождаване и неговото използване

Country Status (40)

Country Link
EP (2) EP1135128B1 (bg)
JP (1) JP2003521455A (bg)
KR (2) KR20010080440A (bg)
CN (3) CN1771943A (bg)
AP (2) AP2005003432A0 (bg)
AR (2) AR029317A1 (bg)
AT (1) ATE366573T1 (bg)
AU (1) AU768303B2 (bg)
BG (2) BG110061A (bg)
BR (1) BR9915284A (bg)
CA (1) CA2350425C (bg)
CO (1) CO5150158A1 (bg)
CY (1) CY1106892T1 (bg)
CZ (1) CZ299801B6 (bg)
DE (1) DE69936533T2 (bg)
DK (1) DK1135128T3 (bg)
DZ (1) DZ2938A1 (bg)
EA (2) EA200700968A1 (bg)
ES (1) ES2289833T3 (bg)
GB (1) GB9824893D0 (bg)
HK (1) HK1041202B (bg)
HR (1) HRP20010344B1 (bg)
HU (1) HUP0104262A3 (bg)
IL (1) IL143088A0 (bg)
MA (1) MA26759A1 (bg)
MY (1) MY128347A (bg)
NO (1) NO328391B1 (bg)
NZ (1) NZ527132A (bg)
OA (1) OA12193A (bg)
PE (1) PE20001239A1 (bg)
PL (1) PL349421A1 (bg)
PT (1) PT1135128E (bg)
RS (1) RS50130B (bg)
SK (1) SK286357B6 (bg)
TR (1) TR200101348T2 (bg)
TW (1) TWI234456B (bg)
UA (1) UA79730C2 (bg)
UY (2) UY25797A1 (bg)
WO (1) WO2000027341A2 (bg)
ZA (1) ZA200103793B (bg)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
ES2259736T3 (es) * 2001-12-21 2006-10-16 Smithkline Beecham Corporation Regimen de dosificacion para activadores de ppar-gamma-.
WO2012074375A1 (en) * 2010-12-01 2012-06-07 N.V. Nutricia Prevention or treatment of overweight and obesity in type 2 diabetic patients

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469331A (ja) * 1990-07-10 1992-03-04 Asahi Chem Ind Co Ltd 徐放性エマルジョン製剤
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0601001B1 (en) * 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Liquid food product containing 3-guanidinopropionic acid
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478853A (en) * 1992-10-12 1995-12-26 Adir Et Compagnie Thazolidinedione compounds
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
CA2115587A1 (en) * 1993-02-18 1994-08-19 Hayato Kihara Styrene copolymers, polystyrene compositions, processes for producing styrene copolymers, and injection-molded articles
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
JP3081245B2 (ja) * 1993-09-15 2000-08-28 三共株式会社 Ｎｉｄｄｍの発症を阻止又は遅延するためのチアゾリジンジオン類の用途
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
NO20012301D0 (no) 2001-05-10
MY128347A (en) 2007-01-31
IL143088A0 (en) 2002-11-10
DE69936533T2 (de) 2008-03-13
CN1771943A (zh) 2006-05-17
NO328391B1 (no) 2010-02-08
AU768303B2 (en) 2003-12-04
AP2005003432A0 (en) 2005-12-31
CA2350425C (en) 2009-06-02
UY25801A1 (es) 2000-08-21
HK1041202B (zh) 2007-10-05
ATE366573T1 (de) 2007-08-15
EA200100539A1 (ru) 2001-12-24
CA2350425A1 (en) 2000-05-18
KR20070048279A (ko) 2007-05-08
DE69936533D1 (de) 2007-08-23
JP2003521455A (ja) 2003-07-15
CZ20011656A3 (cs) 2002-06-12
NO20012301L (no) 2001-07-09
KR20010080440A (ko) 2001-08-22
DZ2938A1 (fr) 2004-03-15
PT1135128E (pt) 2007-10-12
GB9824893D0 (en) 1999-01-06
CN101244062A (zh) 2008-08-20
HK1041202A1 (en) 2002-07-05
YU37401A (sh) 2005-07-19
WO2000027341A3 (en) 2000-09-08
BG65577B1 (bg) 2009-01-30
ES2289833T3 (es) 2008-02-01
EA009192B1 (ru) 2007-12-28
CY1106892T1 (el) 2012-01-25
DK1135128T3 (da) 2007-11-05
HRP20010344A2 (en) 2002-06-30
PE20001239A1 (es) 2000-12-24
NZ527132A (en) 2005-01-28
SK286357B6 (sk) 2008-08-05
TR200101348T2 (tr) 2002-02-21
MA26759A1 (fr) 2004-12-20
CO5150158A1 (es) 2002-04-29
TWI234456B (en) 2005-06-21
RS50130B (sr) 2009-03-25
CN1354661A (zh) 2002-06-19
UA79730C2 (en) 2007-07-25
HRP20010344B1 (en) 2008-02-29
AP1580A (en) 2006-02-24
BG110061A (bg) 2008-12-30
EA200700968A1 (ru) 2008-06-30
AR029149A1 (es) 2003-06-18
EP1135128A4 (en) 2003-07-16
PL349421A1 (en) 2002-07-29
EP1135128A2 (en) 2001-09-26
WO2000027341A2 (en) 2000-05-18
UY25797A1 (es) 2000-12-29
BR9915284A (pt) 2002-02-13
EP1135128B1 (en) 2007-07-11
HUP0104262A3 (en) 2003-06-30
CZ299801B6 (cs) 2008-11-26
EP1759698A1 (en) 2007-03-07
AU1719600A (en) 2000-05-29
SK6422001A3 (en) 2001-12-03
AR029317A1 (es) 2003-06-25
ZA200103793B (en) 2002-06-05
CN1235586C (zh) 2006-01-11
HUP0104262A2 (en) 2002-08-28
OA12193A (en) 2006-05-09

Similar Documents

Publication Publication Date Title
EP2135603A3 (en) Compositions and methods for increasing insulin sensitivity
WO1998046588A3 (en) Compounds and therapies for the prevention of vascular and non-vascular pathologies
DE3569836D1 (en) Disinfecting method and compositions
CY1107752T1 (el) Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
WO2005012485A3 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
MXPA05007470A (es) Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2.
EA200101089A1 (ru) Новый способ лечения
WO2000007575A3 (en) Methods and compositions for increasing insulin sensitivity
ID30237A (id) KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES
AU2001293851A1 (en) Stabilized hydrogen peroxide solutions
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
KR900002789A (ko) 안과용 용액을 보존하는 방법 및 이를 위한 조성물
NZ600269A (en) Delivery device for treatment of mastitis
ID27765A (id) Plester gel yang mengandung steroid dan proses pembuatannya
BG105569A (bg) Метод за лечение на захарен диабет тип 2
BR9915214A (pt) Combinações contendo um beta-agonista e umagente anti-diabético adicional
AP9901720A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
ECSP993217A (es) Nuevo metodo tratamiento vii
MXPA02012315A (es) Compuesto farmaceutico que contiene silimarina y carbopol, su proceso de fabricacion y su uso como regenerador del tejido y celulas pancreaticas de secrecion endogena danados por diabetes mellitus.
MXPA04000517A (es) Medicamentos profilacticos de ascitis para aves de corral.
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
NZ503862A (en) Use of insulin sensitisers (especially thiazolidinediones) for the treatment of hyperglycaemia
Rugmony et al. Uptake of lead(Pb) and cadmium(Cd), and their effects on certain enzymes of the estuarine gobiid fish, Boleophthalamus dussumierii
NO982854D0 (no) Nitrogenoksyd (NO) syntetase-inhibitor for Õ behandle eller forebygge type II diabetes
TR200000957T2 (tr) Hiperglisemi tedavisinde tiazolidinedion kullanımı